References
Strausz, J., Rolski, J., Aziz, Z., Guckert, M. E., Wright, R. R., Thorn, S., et al. (2008). Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC) [Abstract 20585]. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings, Part I, 26(19S), 731s.
Natanson, C., Kern, S. J., Lurie, P., Banks, S. M., & Wolfe, S. M. (2008). Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA, 299(19), 2304-2312.